Churg-Strauss syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(20 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Churg-Strauss syndrome}}
{{Churg-Strauss syndrome}}


{{CMG}}{{APM}}{{AE}}{{KW}}
{{CMG}}{{APM}}{{AE}}{{CK}}
==Overview==
==Overview==
The prevalence of Eosinophilic granulomatosis with polyangiitis ranges from 2 to 13 per million persons per year, with higher prevalences seen in Europeans.<ref name="pmid14872461" />
The [[incidence]] of [[eosinophilic granulomatosis with polyangiitis]] ranges from 2.5 to 16.6 per 100,000 individuals.  [[Prevalence]]  ranges from 2 to 16 per 100,000 individuals. Mean age at [[diagnosis]] is usually around 45-50 years. In general, [[eosinophilic granulomatosis with polyangiitis]] affects men and women equally.
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Prevalence===
===Prevalence===
The prevalence of Eosinophilic granulomatosis with polyangiitis ranges from 2 to 13 per million persons per year.<ref name="pmid14872461">{{cite journal| author=Mahr A, Guillevin L, Poissonnet M, Aymé S| title=Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. | journal=Arthritis Rheum | year= 2004 | volume= 51 | issue= 1 | pages= 92-9 | pmid=14872461 | doi=10.1002/art.20077 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14872461  }} </ref>
The [[prevalence]] of [[eosinophilic granulomatosis with polyangiitis]] ranges from 2 to 16 per 100,000 individuals.<ref name="pmid15073927">{{cite journal |vauthors=Martin RM, Wilton LV, Mann RD |title=Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies |journal=Pharmacoepidemiol Drug Saf |volume=8 |issue=3 |pages=179–89 |date=May 1999 |pmid=15073927 |doi=10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.0.CO;2-K |url=}}</ref>
 
===Incidence===
===Incidence===
The incidence of Eosinophilic granulomatosis with polyangiitis ranges from 0.5 to 6.8 per million persons per year.  
The [[incidence]] of [[eosinophilic granulomatosis with polyangiitis]] range from 2.5 to 16.6 per 100,000 individuals.<ref name="pmid11926627">{{cite journal |vauthors=Loughlin JE, Cole JA, Rothman KJ, Johnson ES |title=Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients |journal=Ann. Allergy Asthma Immunol. |volume=88 |issue=3 |pages=319–25 |date=March 2002 |pmid=11926627 |doi=10.1016/S1081-1206(10)62015-7 |url=}}</ref>
 
==Demographics==
==Demographics==
The rate distribution of Eosinophilic granulomatosis with polyangiitis varies upon age, sex, and race.
===Age===
===Age===
The mean age of diagnosis of Eosinophilic granulomatosis with polyangiitis is 48 years of age. The incidence of the disease in female patients is between the ages of 14 to 74 years of age. The age for males is comparable to that of female patients with the disease.
The mean age at  diagnosis of [[eosinophilic granulomatosis with polyangiitis]] is around 45-50 years.


===Gender===
===Gender===
There is no sex predominance for Eosinophilic granulomatosis with polyangiitis. <ref name="pmid24530234">{{cite journal| author=Mouthon L, Dunogue B, Guillevin L| title=Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). | journal=J Autoimmun | year= 2014 | volume= 48-49 | issue=  | pages= 99-103 | pmid=24530234 | doi=10.1016/j.jaut.2014.01.018 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24530234  }}</ref>
In general, there is no gender predilection to  [[eosinophilic granulomatosis with polyangiitis]] in western nations. In Japan, female predominance has been noted.<ref name="pmid24289197">{{cite journal |vauthors=Sada KE, Amano K, Uehara R, Yamamura M, Arimura Y, Nakamura Y, Makino H |title=A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan |journal=Mod Rheumatol |volume=24 |issue=4 |pages=640–4 |date=July 2014 |pmid=24289197 |doi=10.3109/14397595.2013.857582 |url=}}</ref>


===Race===
===Race===
The race most commonly that affects Eosinophilic granulomatosis with polyangiitis is poorly documented. However, prevalence of the disease is seen both in Asian and European populations with an equal distribution.<ref name="pmid21674413">{{cite journal| author=Gibelin A, Maldini C, Mahr A| title=Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. | journal=Semin Respir Crit Care Med | year= 2011 | volume= 32 | issue= 3 | pages= 264-73 | pmid=21674413 | doi=10.1055/s-0031-1279824 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21674413  }}</ref>
In general, there is no racial predominance to [[eosinophilic granulomatosis with polyangiitis]].


==References==
==References==

Latest revision as of 13:50, 10 April 2018

Churg-Strauss syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Churg-Strauss syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Churg-Strauss syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Churg-Strauss syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Churg-Strauss syndrome epidemiology and demographics

CDC on Churg-Strauss syndrome epidemiology and demographics

Churg-Strauss syndrome epidemiology and demographics in the news

Blogs on Churg-Strauss syndrome epidemiology and demographics

Directions to Hospitals Treating Churg-Strauss syndrome

Risk calculators and risk factors for Churg-Strauss syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [3]

Overview

The incidence of eosinophilic granulomatosis with polyangiitis ranges from 2.5 to 16.6 per 100,000 individuals. Prevalence ranges from 2 to 16 per 100,000 individuals. Mean age at diagnosis is usually around 45-50 years. In general, eosinophilic granulomatosis with polyangiitis affects men and women equally.

Epidemiology and Demographics

Prevalence

The prevalence of eosinophilic granulomatosis with polyangiitis ranges from 2 to 16 per 100,000 individuals.[1]

Incidence

The incidence of eosinophilic granulomatosis with polyangiitis range from 2.5 to 16.6 per 100,000 individuals.[2]

Demographics

Age

The mean age at diagnosis of eosinophilic granulomatosis with polyangiitis is around 45-50 years.

Gender

In general, there is no gender predilection to eosinophilic granulomatosis with polyangiitis in western nations. In Japan, female predominance has been noted.[3]

Race

In general, there is no racial predominance to eosinophilic granulomatosis with polyangiitis.

References

  1. Martin RM, Wilton LV, Mann RD (May 1999). "Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies". Pharmacoepidemiol Drug Saf. 8 (3): 179–89. doi:10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.0.CO;2-K. PMID 15073927.
  2. Loughlin JE, Cole JA, Rothman KJ, Johnson ES (March 2002). "Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients". Ann. Allergy Asthma Immunol. 88 (3): 319–25. doi:10.1016/S1081-1206(10)62015-7. PMID 11926627.
  3. Sada KE, Amano K, Uehara R, Yamamura M, Arimura Y, Nakamura Y, Makino H (July 2014). "A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan". Mod Rheumatol. 24 (4): 640–4. doi:10.3109/14397595.2013.857582. PMID 24289197.

Template:WH Template:WS